2.62
-0.14 (-5.07%)
| Previous Close | 2.76 |
| Open | 2.75 |
| Volume | 2,055,159 |
| Avg. Volume (3M) | 1,705,681 |
| Market Cap | 257,759,104 |
| Price / Sales | 0.510 |
| Price / Book | 0.760 |
| 52 Weeks Range | |
| Earnings Date | 12 Mar 2026 |
| Profit Margin | -15.96% |
| Operating Margin (TTM) | -9.49% |
| Diluted EPS (TTM) | -0.700 |
| Quarterly Revenue Growth (YOY) | 10.30% |
| Total Debt/Equity (MRQ) | 2,020.06% |
| Current Ratio (MRQ) | 1.79 |
| Operating Cash Flow (TTM) | -15.64 M |
| Levered Free Cash Flow (TTM) | 5.58 M |
| Return on Assets (TTM) | -17.66% |
| Return on Equity (TTM) | -277.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Care Facilities (US) | Bullish | Mixed |
| Medical Care Facilities (Global) | Bullish | Bullish | |
| Stock | The Oncology Institute, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -3.5 |
| Average | 0.00 |
|
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services. |
|
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| Investment Style | Small Value |
| % Held by Insiders | 9.22% |
| % Held by Institutions | 34.63% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Josh Arnold Investment Consultant, Llc | 31 Dec 2025 | 2,459,809 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (BTIG, 167.18%) | Buy |
| Median | 6.00 (129.01%) | |
| Low | 5.00 (Needham, 90.84%) | Buy |
| Average | 6.00 (129.01%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 2.73 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 09 Mar 2026 | 7.00 (167.18%) | Buy | 2.73 |
| Needham | 09 Mar 2026 | 5.00 (90.84%) | Buy | 2.73 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook |
| 09 Jan 2026 | Announcement | The Oncology Institute Announces Leadership Promotions |
| 05 Jan 2026 | Announcement | The Oncology Institute Announces Addition of Board Member Mark Stolper |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |